Author Archives: Fredricko

Lacking chemistry, Mystics react well enough to hold off the Dream – Washington Post

Posted on by

Ahead of the Washington Mystics 78-72 win over Atlanta on Sunday, Mystics Coach Mike Thibault was asked to describe the progress his retooled roster is making toward becoming a cohesive unit. His response was simple.

Slow, he said.

That disconnect showed Sunday, when for the second straight game Washington needed the final seconds to seal a home win. The Mystics (5-2) staved off an impressive comeback from Atlanta after frittering away an 18-point lead. Washington trailed 72-71 with 43 seconds left before it won the game at the foul line, with Elena Delle Donne hitting five free throws and Shatori Walker-Kimbrough sinking two as the Dream (4-2) missed its final two field goals.

Its hard, eight players, we got tired legs shooting the ball, Thibault said. ... But its really nice to have one of the best players in the league on your team when youre down the stretch.

[Mystics Ivory Latta has a book and a message]

Delle Donne led Washington with 23 points and a career-high 15 rebounds and hit 10 of her 12 free throw attempts. Tierra Ruffin-Pratt added 11 points, and a hot-handed Kristi Toliver had 15 on a season-high five three-pointers.

Washington was without starting guard Tayler Hill (neck/left shoulder strain) and backups Natasha Cloud (left knee strain) and Asia Taylor (neck pain), but a shortened rotation is just one of the reasons team chemistry on offense was spotty Sunday.

A month into the season, the Mystics are integrating six new players. Starting forward Emma Meesseman is overseas with the Belgian national team, and Toliver is still catching up after missing all of training camp.

Hills injury also forced Walker-Kimbrough into the starting lineup just four games into her WNBA career. Her first task as a starter was no easy ask the former Terp had to guard Eastern Conference player of the month Tiffany Hayes, who averages 19.8 points and had 24 against the Mystics.

All that offensive adjustment resulted in Washingtons second shoddy shooting game in a row: The Mystics shot 36.5 percent from the field Sunday.

I just think were operating at about 50 percent offensively right now, Thibault said.

His star player agreed, though no one in the Mystics locker room is fretting. The win put Washington ahead of Atlanta at the top of the Eastern Conference and in second place in the league overall behind undefeated Minnesota.

We have great moments, and then we have some bad moments, Delle Donne said. But its early in the season, and its kind of expected. Were a brand-new team, and were all trying to figure one another out. Obviously I hope to see us improve each game and get better and better, but until then, we just have to continue to be really good on defense.

Defense helped Washington dominate the first half. Hot shooting from Toliver, who had three three-pointers in the first three minutes of the game, got the Mystics off to a good start, and they kept Atlantas offense from getting out in transition as they went on lengthy runs at the start of the second and third quarters.

With Walker-Kimbrough on her, Hayes got to the free throw line only twice in the first half and was held to just seven points.

But breakdowns crept in midway through the third quarter, when Hayes finally pushed through a tired Washington defense and the Mystics sputtering offense lost its safeguard.

Hayes had seven points in the third quarter alone. Washington ended the game with 14 turnovers to Atlantas three, many of them a result of miscommunication.

I thought we had two terrible possessions on offense where causal, not executing what we called, then we watched us shoot a jump shot, and while were watching, theyre out running two-on-one a couple times, Thibault said of third quarter. They had us on our heels a little bit.

Delle Donne stepped in when the Mystics were really reeling, after Sancho Lyttle nabbed Atlantas first lead of the game with a 12-foot jumper with 43 seconds to play. Washington came out of a timeout with the ball, and Delle Donne drew a three-shot foul when Lyttle jumped to block her shot far too early.

Walker-Kimbroughs two free throws with four seconds left provided insurance and accounted for two of the rookies three points Sunday. Her first career start was a solid one defensively, and she may be seeing more minutes soon.

Hill strained her neck in Wednesdays win over Connecticut but could play this week. Cloud had a gnarly collision with Taylor in practice Friday, and an MRI exam Saturday morning revealed a left knee strain. There is no timetable for Clouds return.

For now, at least, she is another missing piece for Washington to work around.

New York tops Phoenix

Kiah Stokes scored a career-high 23 points and added 14 rebounds to help the New York Liberty beat the visiting Phoenix Mercury, 88-72.

Its the second straight game that Stokes has had a career high in points and finished with a double-double. I think shes in a good place and I think shes shown great progress, New York Coach Bill Laimbeer said of Stokes.

Shavonte Zellous added 21 points, and Tina Charles had 16 for New York (4-3).

Brittney Griner scored 26 points, and Diana Taurasi added 17 for Phoenix (4-3).

Associated Press

More here:
Lacking chemistry, Mystics react well enough to hold off the Dream - Washington Post

Football, paramedic career, UMSL chemistry lead Chris Tipton to med school – UMSL Daily (blog)

Posted on by

Chris Tipton poses next to the helicopter he works on as a critical care flight paramedic for Survival Flight Inc. Paramedic medicine inspired Tipton to go back to school for a masters degree in chemistry. The UMSL spring grad is now headed to medical school at Mizzou, where he used to play football while earning his bachelors degree in agricultural science. (Photo by August Jennewein)

At first glance, Chris Tipton appears an odd fit in a laboratory. The hulking former Mizzou Tiger offensive linemans big stature looks potentially hazardous surrounded by glassware and equipment.

But the truth is, Tipton is right at home. The soon-to-be masters in chemistry graduate works as a research assistant for Professor Chris Spilling at the University of MissouriSt. Louis when he isnt busy being a part-time critical care flight paramedic for Survival Flight Inc.

Through football Tipton indirectly found his true calling in medicine.

After graduating from the University of MissouriColumbia in 2007 with a bachelors degree in agricultural science, Tipton started a career path popular among his football buddies firefighting. In his training to get his emergency medical technician and paramedic licenses, he discovered he liked treating the patients more than the fire.

Tipton took a ground paramedic job in Northeast Missouri shortly thereafter and eventually became the lead paramedic for Pike County.

You handle people on the worst day of their lives, Tipton says. Youre the first person a lot of times that this person will be seeing in their whole continuum of care. So its really important, the job we do.

In his first week, Tipton delivered a baby on the side of a highway.

Youre almost scared for the tones to go off, says Tipton, recalling his early days on the job.

Hes been a paramedic for nine years now, spending the last four and half of those in the air not a place paramedics start off.

You get the sickest of the sick, he says. You might only run one call a day, but that one call has you go through almost every single skill youve possibly learned and all kinds of drugs that you would maybe use in a months time as a ground paramedic.

After some years, Tipton started to feel as if he had maxed out his paramedic certification. A drive to do more in the field of medicine led him back to school, specifically to UMSL, where he could get a masters degree and some more science classes and research under his belt before applying to medical school.

Dr. Spilling has given me a tremendous opportunity, says Tipton, who is fully funded and receives a stipend. That was the only way I could go part time as a paramedic and pursue research full time.

In the lab at UMSL, he works on creating novel therapeutic compounds for people who suffer from sepsis, a type of blood poisoning. Hes also found a lot of value in his UMSL coursework.

Class after class, light bulbs go off, he says. Ive learned a lot of the concepts at the paramedic level, but now Im learning them at the cellular and molecular levels.

Tipton scored in the 93rd percentile in the science sections of the MCAT. Hes returning to his old stomping grounds this summer, not as a football player, but as a student in Mizzous medical school/PhD program. Tipton plans on conducting cancer research and possibly doing a residency in pathology or immunology.

Helping people is a huge part of why I do what I do, he says. What Ive gotten from UMSL is seeing how the science translates to that.

This story was originally published in the spring 2017 issue ofUMSL Magazine. Have a story idea for UMSL Magazine? Email magazine@umsl.edu.

Short URL: http://blogs.umsl.edu/news/?p=68708

Here is the original post:
Football, paramedic career, UMSL chemistry lead Chris Tipton to med school - UMSL Daily (blog)

How I Aced Biochemistry – PreMedLife – The Lifestyle Magazine for Pre-Medical Students

Posted on by

College hallways abound with rumors on the blood, sweat, and tears that accompany biochemistry. Mechanisms, pathways, enzymes Anxiety crept upon me after I signed up for the class and anticipated syllabus day until I stood up, determined, that I willsucceed biochemistry! I understand the heavy workload, tediousness, and specificity of the material, so I would like to share a handful tips on how I aced the class!

When we hear judgments, we could feasibly become influenced by their opinions and prejudge our experiences before we even set foot. I eventually decided to block out peoples opinions on the class, and focus on making the course my own experience. It is crucial to realize other peoples experiences do not determine yours. Further, avoid assuming the nature of the class. It may be boring, and on top of that, nearly impossible! I just hate memorizing pathways! Your attitude affects your performance. Perhaps, approach with a more open viewpoint of the class: It might be challenging, but Im open to learning about the underlying machinery of the human body. If you already find biochemistry intriguing, you are ahead of step one!

Some professors provide students with lecture notes online to print, as others do not. If your professor does not, recording the lecture could help tremendously to go back and listen to what you may have missed or to gain a more solid understanding. If the professor does provide online lecture notes, make sure to print them or download them onto your computer. I read over the lecture notes the same day of the class and quizzed myself over simple questions on the material on the notes. (Keep in mind: biochemistry includes application, critical thinking, and memorization, so your exam most likely may ask questions on a deeper level, but understanding the basics of the lecture is the point of quizzing yourself over the lecture notes). I divided the notes into sections and turned the stated lecture notes into questions to ask and quiz myself over. With this step, you will be familiar with what was covered in class.

A helpful way to perform on exams is to ask the professor if the lecture notes or textbook serve more as a basis for the exams. I studied lecture notes and read the textbook, regardless of when my professor stated the lecture notes were sufficient for the tests (reading the textbook chapters helped tremendously with the exams!) Not everybody prefers to read textbooks, or even needs the textbook for high performance, so this step depends on personal preference. As the material can be overwhelming, I divided my reading into paragraphs. I would read one paragraph once, read it again and highlight, then write my notes in my own words. Be sure to take breaks too!

You cannot go wrong with getting to know your professor! They could introduce you to resources that can help you, take time to elaborate concepts, and overall, help you along your academic journey. If you do not understand material, be sure to make time to visit your professors office hours with a list of things to ask. Emailing is a great option as well (if your professor checks it!); however, face-to-face interaction facilitates the ability to ask questions.

I am such a visual learner! It can be hard for me to visualize the chymotrypsin mechanism or the way translation works. Looking up these mechanisms on YouTube eased understanding of these concepts because I obtained a visual grasp on how they work.

My professor provided us with practice exams for the class; however, if your professor does not, worry not! I sometimes chose not to go with the exams the professor offered and googled biochemistry practice exams for a particular set of topics. It obviously will most likely not resemble your exams difficulty, application style, etc., but it will help train you to apply your knowledge, rather than soak up everything you have learned without using it. Be sure to practice those math problems too!

I have disappointed myself a few times throughout the class, and overall, my college experience. It happens! We are human. Breathe. What matters is your attitude, which drives the recovery. If you did not get the grade you expected, contact the professor, let him/her aware of your concern and what you can do to perform better next time, go over the exam, go over practice problems, etc. At the end of the day, you are taking a challenging class and are willing to succeed! Give yourself credit for the amazing effort you are putting in! Believe in yourself!

View original post here:
How I Aced Biochemistry - PreMedLife - The Lifestyle Magazine for Pre-Medical Students

Why ‘Grey’s Anatomy’ Jaggie Is the Worst Idea Ever – BuddyTV (blog)

Posted on by

The Grey's Anatomy Season 13 finale introduced us to the world of Jaggie. Apparently this had been teased for a while, but honestly I never saw it. For those who aren't quite sure about shipper names, Jaggie is Jackson and Maggie, who are step-siblings through their parents' (Catherine and Richard) marriage. It's been two weeks since the Grey's Anatomy season finale and fans are still discussing the idea, with the majority agreeing that this is the worst relationship Shonda Rhimes and her writers have ever come up with. I, for one, fully agree with these fans. Jaggie is the worst idea ever for Grey's. The Relationship Came out of Nowhere

I know a lot of fans discussed the idea of Jaggie happening weeks before the season finale. I remember soon after Maggie's mom died and fans said there were hints that they were getting together in those moments of the two together.

Now, fans do have a habit of seeing things that aren't always there. This is the beauty of TV. It's possible to pick up on sly looks or the way someone says a line but have completely different opinions about what the characters actually meant. That scene of Jackson sharing the photos he'd found of Diane with Maggie never looked like a hint of a relationship to me. It looked like a hint of friendship, something that both characters have needed for a very long time.

When April told Maggie that Jackson liked her in the season finale, it felt rushed and unnecessary. The whole idea of Jaggie came out of the blue -- even Maggie didn't realize Jackson had feelings for her.

Jackson and April Had Just Reconnected

Grey's Anatomy fans had been waiting for Japril to happen again for a long time. There have been hints for months that they would find their way back to each other, and then in Montana it finally happened. Jackson and April fans danced around with glee at the idea of this couple finally rekindling their romance.

It's clear that April still has feelings for her ex-husband and vice versa. April is still living with Jackson as they raise their baby together. Bringing Maggie into the mix just complicates matters.

Sure, this can mimic real life, but this just doesn't sit right. There was a big thing about April and Jackson rekindling their relationship and then the idea was just abandoned. April is brushed to one side, as if she never even meant anything to Jackson at all. There Are Too Many Characters to Develop This Relationship

Grey's Anatomy took a lot on in season 13. We saw the relationship between Meredith and Riggs develop (with the problem of Maggie liking Riggs.) Fans had to deal with the Minnick/Webber drama, while trying to support the idea of Arizona finding love with the unlikeable Minnick. On top of that we had the Alex court case problem, mixed with Stephanie being written out of the show.

There is something about Grey's Anatomyseason 13 that just didn't work. There were far too many storylines over the space of 24 episodes, leaving some unfulfilling moments, abandoned/forgotten storylines and difficult-to-follow moments.

Bringing in another couple just doesn't work. Season 14 is already going to have multiple storylines to run. Megan is back, causing all types of drama for Owen and Riggs. Amelia and Owen are still getting through their rough patch, and Bailey needs to reverse the mess she caused by hiring Minnick. There just isn't room for a new (out of the blue) relationship to be introduced.

To top this off, fans just don't want it. They want to see Jackson and April together. Fans want to see the two raise their daughter together.

Do you think Grey's Anatomy's Jaggie will work? What were your thoughts in the first moment you found out Jackson really does have feelings for Maggie? Share your thoughts in the comments below.

Grey's Anatomyseason 14 returns in the fall on Thursdays at 8/7c on ABC. Don't forget to like our Grey's AnatomyFacebook page to get the latest updates and articles straight to your newsfeed.

(Image courtesy of ABC)

Read the original here:
Why 'Grey's Anatomy' Jaggie Is the Worst Idea Ever - BuddyTV (blog)

‘Grey’s Anatomy’ Season 14 spoilers: Meredith, Nathan together again? – Blasting News

Posted on by

Fans are hoping to see Meredith and Nathan together again in the upcoming Season 14 of "#Grey's Anatomy." So, what should the fans expect in the new season of the hit ABC drama?

According to new reports, Meredith (Ellen Pompeo) and Nathan (Martin Henderson) might be able to continue their relationship in "Grey's Anatomy" Season 14. Their relationship could finally get through the struggles that fans saw in the ending of GA Season 13.

There is no doubt that "Grey's Anatomy" Season 13 left a lot of cliffhangers in the story. Speculations are making the rounds that Meredith and Nathan might finally rekindle their romance in the upcoming GA Season 14.

Meredith and Nathan's relationship was affected by the return of Megan. In Season 13 of the show, Megan, Owen's sister, and Nathan's fiance were found to be alive after disappearing for several years. People thought she had already died, but the lives and relationship of Nathan and Meredith will change now that she is back. Although Meredith and Nathan's romance was just getting started, it seems like it has already ended now that Megan is back.

During the Season 13 finale of the show, Meredith was the one who broke the news to Nathan. She told hem that Megan is actually alive and urged him to visit her. Meredith even told Nathan that she would have rushed to Derek if she knew he was alive. It seems like Meredith is willing to give up Nathan just to see him happy. However, fans are worried about the future and happiness of Meredith.

It was clear that Meredith was actually ready to introduce Nathan to her kids as her boyfriend. She was even ready to let her friends know that he and she are already dating. However, Megan's return has affected their new relationship.

Rumors are now making the rounds that Megan's traumatic experience might cause her to refuse to go with Nathan. If this happens, then Nathan can finally move on with Meredith. Fans are hoping to see the two continue their relationship in GA Season 14.

Reports claimed that the fans are tired of seeing Meredith unhappy, which is why they are hoping to see her end up with Nathan in GA Season 14. Hopefully, the producers of the show can hear the fans out.

"Grey's Anatomy" Season 14 comes back on small screens in the fall and will air every Thursdays at 8/7c on ABC. #Grey's Anatomy Season 14 #Grey's Anatomy meredith

See original here:
'Grey's Anatomy' Season 14 spoilers: Meredith, Nathan together again? - Blasting News

Bsc Biotechnology What Does The Course Cover? – Good Herald

Posted on by

If you are interested in a career in one of the most interesting areas of science then you should consider joining the field of biotechnology. Armed with a BSc Biotechnology degree, you will be able to apply for many interesting and high paying jobs across a number of industries. As a matter of fact, there are quite a few colleges in Dehradun that offer three year graduate programs in biotechnology because there is a great deal of demand for a degree in this field on account of its robust job prospects. Keep in mind that youll generally need to have a background in science (10 + 2) in order to be able to apply for this course because math, biology and chemistry are very important to students in this field.

The field of biotechnology is growing at a very rapid pace and it is also essential to many industries. The importance of this field comes from its ability to use technological methodologies to improve a number of biological systems in order to create new processes and products that have the ability to improve our life overall. The field of biotechnology consists of many different areas of study. Some of the most important ones are Immunology, Molecular Biology, Genetic Engineering, Microbiology and Environmental Biotechnology, just to name a few. Plant and animal biotechnology are also important areas of study.

Since the field of biotechnology is a very vast one that covers many different areas of study, it is best for you to understand which area appeals to you the best before you select a particular program. It is also important to keep in mind that the employment opportunities offered by each area of study differ considerably. Even so, you will find that employment opportunities for a BSc biotechnology graduate are fairly robust.

If you have a BSc Biotechnology degree then you will be able to get employment right away although a Masters degree will brighten your job prospects further. As a graduate, you will be able to get jobs in various fields including chemicals, pharmaceuticals, food processing and agriculture. The government is a very good source of jobs for biotechnologists and so are many large corporate houses. Waste management is a very important area these days and there is great need for biotechnologists who specialize in this area. As you can see, biotechnology is a very large and important field that is worth entering.

For more information on B.Sc Biotechnology. Visit Today http://bfitdoon.com/bsc-biotechnology.php

Photo By OpenClipart-Vectors from Pixabay

Read the original here:
Bsc Biotechnology What Does The Course Cover? - Good Herald

Evolving Biotechnology – Good Herald

Posted on by

There are plenty of explanations of what biotechnology is, but the simplest one is that it is a field of study where biology is the foundation on which different kinds of technology are developed. Biotechnology is the basis of many different kinds of research in the fields of environment, food science, robotics, agriculture and medicine.

The human involvement in manipulating their environment is now at remarkable levels. From the most basic direct organism manipulations such as fermenting beer and culturing bacteria to advanced nucleotide-based organ regeneration and animal cloning, our knowledge and technology has advanced far beyond what anyone wouldve expected just a decade ago.

But even before there was a name to call it by, biotechnology was in existence. Even something that people have been doing for centuries, like preservatives to keep food edible during winter, is a form of biotechnology. When around 6000 BC, fruit juice was first fermented to form alcohol, it was another instance of biotechnology. Of course, it has emerged as a science only recently.

About twenty years ago, the role of genetics in artificially creating proteins in a living being was discovered. DNA was discovered and molecular biology became a part of mainstream science. This was what gave rise to the study of biotechnology under that name.

The mid 80s brought a revelation in biotechnology genetic structures could be modified by careful combinations between animals and plants. This introduction to transgenic organisms also developed an area for further research into disease resistance and productivity rate increases. Modern biotechnology is used in a variety of ways and the medical and biological research fields have managed to get the most benefit out of it. The methods used have gone beyond ordinary genetic transfers, to include actual plant-generated pharmaceuticals and substance production for antibiotics and insulin.

Modern biotechnology is practiced in three different categories red, white and green. Red Biotechnology is when the genetically altered microorganisms are used to produce medical and pharmaceutical substances, such as proteins, vitamins, antibiotics and vaccines etc. Its also used in genome manipulation.

White Biotechnology is also known as bio-manufacturing and Grey Biotechnology. This is not yet a completely established field and involves manipulating live organisms to create important industrial chemicals. Some of the organisms used in these techniques include bacteria, enzymes, moulds and yeast.

Agricultural Biotechnology, also known as Green Biotechnology, is whats applied into creating better, fresher, more nutritious and longer-lasting agricultural produce. A traditional agricultural biotechnology example is how wheat varieties are cross-bred to produce a disease-resistant crop.

If you are looking for the latest biotech news then take a look at this great new website. Full of details about innovations for the biotech industry , you cant afford to miss it. New inventions, ideas and theories make great reading.

Photo By 3dman_eu from Pixabay

Continue reading here:
Evolving Biotechnology - Good Herald

Genetic sequencing could influence treatment for nearly 3/4 of advanced cancer patients – Medical Xpress

Posted on by

June 2, 2017

A new analysis finds that nearly three-quarters of 500 patients with advanced cancer could be referred to a potential targeted treatment based on the results of a comprehensive analysis of their tumor's genetic landscape.

The study suggests the value of so-called next generation sequencing, a sophisticated method of evaluating the DNA and RNA of a tumor to help direct treatment.

A report on the first 500 patients with advanced solid tumors to go through the University of Michigan Comprehensive Cancer Center's sequencing program found that 72 percent qualified for a clinical trial based on a genetic marker in their tumor.

While not all of those patients were able to enroll in a trial based on other eligibility factors and trial location, the number who did enroll doubled from approximately 5 percent of patients in 2012 to 11 percent in 2016. Increased trial enrollment occurred as several major national biomarker-based studies opened.

"Availability of biomarker trials is crucial for being able to act on these results. Over time, we became better at matching patients to clinical trials as more of these basket trials opened," says Erin Cobain, M.D., clinical lecturer of hematology/oncology at the University of Michigan Medical School.

Cobain will present these findings at the American Society of Clinical Oncology annual meeting.

The Michigan Oncology Sequencing Center began in 2011, sequencing the DNA and RNA of metastatic cancers and normal tissue to identify alterations that could help drive treatment. About 900 patients with advanced cancer have enrolled to date. The analysis presented at ASCO focuses on the first 500 patients with solid tumors.

Precision medicine in action

Patients with stage 4 cancer undergo a biopsy and provide a blood sample to test their normal DNA. Patients also receive genetic counseling.

Results of the sequencing are discussed by a team of oncologists, genetics specialists, pathologists, bioinformatics specialists and genetic counselors, among others, at a precision medicine tumor board. This group discusses all results and assesses the feasibility of pursuing treatment options based on the genomic findings.

Genetic sequencing involves looking at all of the DNA and RNA expressed within a tumor. Scientists comb through this enormous amount of data to identify anomalies that may prove to be targets for existing approved or experimental therapies.

In addition, the program sequences patients' normal genome. This means it's able to identify hereditary genetic variations - those inherited from a mother or father and potentially passed down to children. Researchers found these hereditary variations in 11 percent of patients, none of which had been previously identified through family history.

"That was a major surprise. That 11 percent of patients had a genetic change that increases cancer risk is much higher than we would expect. This has significant impact not only on the patients, but on their families, who may also carry a genetic susceptibility to cancer," Cobain says.

A more comprehensive approach

Mi-ONCOSEQ, which is run as a research study, requires a fresh biopsy, where many commercial sequencing tools can use frozen tissue samples. However, those tests analyze only a limited panel of genes. The goal with Mi-ONCOSEQ was to obtain a large enough sample so that researchers could perform extensive sequencing of both DNA and RNA.

The more-thorough analysis, which covers at least 1,700 genes, meant that many anomalies were identified that would not have been found on panel-based tests that typically cover about 350 genes. Because Mi-ONCOSEQ is run as a research study, patients did not pay for sequencing.

Cobain cites an example of a patient with cholangiocarcinoma, a cancer of the bile duct. Sequencing revealed a novel gene fusion that would not have been identified through panel-based tests. The patient was able to enroll on a clinical trial targeting the gene fusion and had an excellent response to that therapy.

"This would not have been found by a commercial assay," Cobain says. "Sequencing is beginning to have a real impact on treatment recommendations. It's important to consider this testing early in the patient's clinical course in order to improve our ability to act on the results and impact the patient's course."

Explore further: Genetic alterations more common in tumors of older patients with metastatic breast cancer

More information: Reference: ASCO Annual Meeting, June 2-6, 2017, abstract 101

A University of North Carolina Lineberger Comprehensive Cancer Center-led analysis has found that women who are 65 years or older with metastatic breast cancer were more likely to have a cancer-linked genetic alterations ...

For children with rare, aggressive and advanced cancer, precision medicine may help doctors determine their best treatment options, a new study finds.

A preliminary study comparing two commercially available, next-generation genetic sequencing tests in the same cancer patients shows results can differ widely. The findings are reported Dec. 15 in JAMA Oncology.

The progression-free survival rate (PFS) in cancer patients treated with targeted therapies (identified using a multigene panel test on their tumor samples) was significantly higher than the PFS in these patients when they ...

Researchers from the University of Michigan Comprehensive Cancer Center and Thermo Fisher Scientific have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates ...

Researchers at the University of Cincinnati (UC) College of Medicine are enrolling patients in a clinical trial looking at targeted gene therapies in patients with early stage lung cancer who have had surgery.

A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene found in many cancers. The pre-clinical study combined ...

The use of immunotherapy to treat cancer is celebrating its first successes but there are still many knowledge gaps in the underlying mechanisms of action. In a study of mice with soft tissue tumors, ETH researchers have ...

A compound found in olive oil may help to prevent cancer developing in the brain, a study shows.

In an effort to starve brain cancer cells and put the brakes on tumor development, University of North Carolina Lineberger Comprehensive Cancer Center researchers blocked the main pathway that brain tumor cells use to convert ...

A common class of chemicals found everywhere from car exhausts, smoke, building materials and furniture to cosmetics and shampoos could increase cancer risk because of their ability to break down the repair mechanisms that ...

For years, cancer experts have realized that cancerous cells behave in certain ways like stem cells, unspecialized cells that when exposed to certain signals, can "differentiate."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Follow this link:
Genetic sequencing could influence treatment for nearly 3/4 of advanced cancer patients - Medical Xpress

Carleton College to hold its 143rd Commencement Ceremony June 10 – Carleton College News

Posted on by

Carleton College will award the Bachelor of Arts degree to the 505 graduating members of the Class of 2017 onSaturday,June 10, in a ceremony beginning at 9:30 a.m. on the lawn west of Hulings Hall on the Carleton campus. A celebratory picnic on the Bald Spot will follow. In the event of severe weather, commencement will be held indoors at the Recreation Center. Seating is available to accommodate all guests, whether outdoors or indoors, and no tickets are required. The ceremony will also be broadcasted live online (https://apps.carleton.edu/events/commencement/livestream/).

Following President Steve Poskanzers opening remarks,Reina Desrouleaux '17, chemistry major from Silver Spring,Maryland (whose speech is titled [insert meaningful life experience here]) and Eli Ruffer '17, chemistry major from Highland Park, Illinois (whose speech is titled Tyler, the Prospective Student)will address the Class of 2017, families and friends, and faculty. In additionally, Carleton College will confer an honorary doctorate upon Kathy L. Hudson 82, former Deputy Director for Science, Outreach, and Policy at the National Institutes of Health, who will briefly address the class.

The highest honor given by the College, conferred honoris causafor the sake of honorthis years honorary degree recipient is Dr. Kathy L. Hudson, former Deputy Director for Science, Outreach, and Policy at the National Institutes of Health (NIH).

Throughout her distinguished career, Hudson has served the public by ensuring that advances in genomics and other rapidly moving areas of medical research are paired with wise and effective public policies.

After earning a B.A. in biology from Carleton College and a M.S. in microbiology from the University of Chicago, Hudson obtained her Ph.D. in molecular biology from the University of California, Berkeley. Although she trained for a career in research, Hudson discovered that her real passion was science policy. As an American Association for the Advancement of Science (AAAS) Fellow in Washington DC, she worked for the U.S. House of Representatives and then the Congressional Office of Technology Assessment.

After a stint in the office of the Assistant Secretary for Health at the Department of Health and Human Services, Hudson joined the National Human Genome Research Institute (NHGRI) as assistant director. While there she made a compelling case to scientists, public policy experts, and lawmakers about the need for federal legislation to guard against genetic discrimination. She also helped to broker an historic agreement between the public and private human genome projects, which was announced by President Bill Clinton in the White House in 2000.

In 2002, Hudson left NHGRI to found and direct the Genetics and Public Policy Center at Johns Hopkins University. She became a leader in educating and advising about science and policy issues in genetics. Also at Hopkins, Hudson was an Associate Professor in the Institute of Bioethics and the Institute of Genetic Medicine. It was Hudson who did much of the work to assemble the talented and dedicated team that, in 2008 after years of effort, achieved passage of the landmark Genetic Information Nondiscrimination Act.

In 2009, Hudson returned to the National Institutes of Health, becoming the Deputy Director for Science, Outreach, and Policy. In that capacity helped found and launch the National Center for Advancing Translational Sciences. She also had a major hand in the design and launch of three national scientific projects the BRAIN Initiative, the Precision Medicine Initiative, and the Cancer Moonshot. In addition, she led efforts to revise the rules that govern participation of human subjects in research, modernize clinical trial reporting, expand scientific data sharing, and develop appropriate oversight for rapidly moving areas of medical research, including stem cells and gene editing.

On top of her many duties and responsibilities, Hudson made time to serve as a strong and tireless advocate for the role of women in science. She personally mentored a group of young women who are now moving into key leadership roles with a wide range of innovative biomedical research and policy initiatives.

Earlier this year Hudson left government service, and is working as an advisor to companies and research institutes as they forge new directions at the forefront of biomedical research.

For further information, including disability accommodations, contact the Carleton College Office of College Communications at(507) 222-4309or emailkraadt@carleton.edu. The commencement site is located on the Carleton campus between College and Winona Streets in Northfield.

More:
Carleton College to hold its 143rd Commencement Ceremony June 10 - Carleton College News

Sweet Briar College | News | Sweet Briar launches Explore … – SBC News

Posted on by

June 2, 2017 | Janika Carey

High school women interested in STEM can now explore a whole range of subjects at Sweet Briar College. Chemistry is joining engineering, environmental science and math, with the first Explore Chemistry Weekend for High School Girls scheduled for Sept. 22 and 23.

The weekend is open to high school girls in their sophomore, junior and senior years. Participants will receive an introduction to chemistry through one of two hands-on projects with a Sweet Briar chemistry professor. Working in teams, they will collect samples from the campus environment, extract the chemical components and analyze them using state-of-the-art instrumentation.

This will be a great way for high school students to gain a firsthand glimpse of what it is chemists actually do, says Abraham Yousef, associate professor of chemistry and chair of the department. We have access to acres of forested land with an abundance of plant and animal life, and we can show students how chemists identify and quantify some of the chemical substances in our environment.

The weekend kicks off with an optional campus tour at 4 p.m. Friday, Sept. 22, followed by dinner and a project introduction. After staying the night in campus housing with student mentors, participants will spend Saturday working in teams on a research project of their choice. The day wraps at 6 p.m. with a project exhibition and dinner at the Colleges tranquil boathouse.

The $35 fee includesroom and board, snacks, supplies and a T-shirt. Participants are encouraged to register by Sept. 1 for highest priority. Space is limited to 16 students, and only fully paid event registrations reserve a students spot.

For more information, contact Yousef at (434) 381-6197 or ayousef@sbc.edu. To register, click here.

Originally posted here:
Sweet Briar College | News | Sweet Briar launches Explore ... - SBC News

Does the Giants’ lack of in-house Latin players impact clubhouse … – Yahoo Sports

Posted on by

Andrew Baggarly of the Mercury News has a story about the San Francisco Giants minor league woes. All of their affiliates are in last place at the moment and few if any of their prospects are advancing as quickly as the club would like to see.

One of the issues Baggarly identifies is the Giants poor track record in developing international talent, noting that no Giants player from a Latin American country who was originally signed by the Giants has played for the big league club this year (one,Reyes Moronta, spent one day on the 25-man roster but did not play). All of the others were acquired via trade or free agency.

Baggarly suggests that the relatively small number of Latin players on the Giants roster, and the fact that none of them came up through the Giants system together, may be impacting the Giants clubhouse. Here he calls back to a Johnny Cueto quote from April:

When I was with Kansas City, it was a team, I think, it was a very happy bunch because we had a lot of players from the Dominican, Cueto said through Spanish interpreter Erwin Higueros in April. The same with Cincinnati. But here, its different. As Latins, we like to get together kind of loud, and be a happy bunch. But here, you look around and everyone is on their own, just sitting at their locker, very quiet, just by themselves. Thats just how they are.

I had missed that quote when it first came up in April. It seems tangential at best to Baggarlys thesis about the Giants developmental issues, but I find it interesting to consider all the same in light of the Giants sitting in last place.

On one level, obviously, it comes off as a negative comment. After all, when a player says that one club he played for felt like a team and that current club feels like something different, that has to be taken as a negative, yes? To Cueto, the Giants, dont feel like a team and thats never something good to hear from a ballplayer.

Still, its worth noting that the quote came from a couple of months ago. At the time Cueto said that, the season was young, the Giants were expected to be pretty good and, as such, it could be taken as a mostly neutral observation, not some comment about why the Giants arent playing well. Indeed, if the Giants were in first place now it could be seen, perhaps, as almost a compliment. The Giants are a serious, business-minded bunch who let their playing do the talking!

But here it is, reappearing now, when the Giants stink, both at the big league level and in the minors, and it is clearly being offered as a potential reason for why they stink. A lack of Latin players perhaps harming their on-field talent, sure, but also harming clubhouse chemistry and making AT&T Park a dreary place to be.

I dont have a view about the Giants talent base or their clubhouse chemistry as I was only in it for, like, an hour back in Scottsdale in March. But I do find it interesting how player comments can, depending on what is going on with the club on the field at any given time, be seen in many different ways. And how, as always, the conversation about clubhouse chemistry is so often a backwards-looking thing.

View original post here:
Does the Giants' lack of in-house Latin players impact clubhouse ... - Yahoo Sports

Biotechnology: An Overview – Good Herald

Posted on by

Application of technologies on biological systems, dead organisms and their derivatives and food and medicine can be broadly defined as biotechnology. It never had a particular definition since its applications and implementations on various other areas of science are enormous. From manipulating crops and plants to increase the yield to transfer of genes from one organism to the other biotechnology encompasses almost all the living and non-living entities on earth. With the drastic improvement in various machineries and equipments used in the processing of biological materials and the examining of microscopic organisms biotechnology has come a far way since the traditional days of fermentation like techniques, which also is a part of biotechnology.

In the earlier times, biotechnologys application was limited to agriculture and in the production of fermented food products but with the discovery of newer and much complicated data comprising of the most smallest of structures that are measured in microns biotechnology has been found fruitful in the production of many useful products that improves the quality of life of mankind. The categories of science like genetic engineering, animal cell culture, plant cell culture, microbiology, molecular biology, cytogenetics, cryopreservation, bioprocessing, biochemistry, cell biology, embryology, immunology and bioinformatics all these come under biotechnology.

Biotechnology has wide prospects when it comes to environmental science as well. It is used to recycle and retreat the wastes that are left behind at contaminated sites by various industries. This process is termed as bioremediation. Many experiments concerning DNA and RNA and other molecular structures in the human body also comprise of a wide area of practical biotechnology. Mapping of the genes has risen a lot of interest in this decade and with the completion of the Human Genome Project newer prospects for biotechnology has paved way.

Biotechnology has found promising applications in pharmaceutical manufacturing as well. From the production of antibiotics to the purification and separation processes for biomolecules. Biotechnology has its presence felt almost everywhere. Biotechnology plays a massive role in the field of medicine as well. As more and more genetic diseases are brought into picture it is through biotechnology that we try and find ways and means of manipulating the genes and discovering the cure for the disease.

Also with the depleting natural resources for fuel and the environmental effects caused by the use of the conventional fuels can be curbed to a certain extent with the proper manifestation of biotechnology in the production of biorenewable fuel from crops. Biotechnology can speed the production of ethanol and methane for natural gas from these crops.

Overall, biotechnology improves the quality of life and brings in new horizons of modern techniques in various aspects of human life.

The author of this article has great knowledge on Biotechnology. He has written many articles on Chromatography with the great knowledge. He has a great deal of knowledge in Pharmaceutical information as well.

Photo By qimono from Pixabay

Go here to read the rest:
Biotechnology: An Overview - Good Herald

Anatomy of the collusion lie – Power Line (blog)

Posted on by

Our friends at that American Greatness site are pushing back on the alleged collusion scandal narrative. Andy McCarthys Real collusion was the first in a series. Brandon Weichert and Chris Buskirks The anatomy of a lie (i.e., the Trump-Russia collusion scandal) is the second. It aims to tell how the Russia story evolved from a campaign talking point into a witch hunt in search of a crime. Weichert and Buskirk have also produced a 30-minute video to accompany their anatomy; the video is embedded in their essay.

The Weichert/Buskirk anatomy compiles a substantial amount of information and turns it into a narrative with links to relevant source materials. The video gives a timeline documenting how the claim that Donald Trump colluded with Russia in order to steal the 2016 U.S. presidential election evolved. It argues the falsity of the claims of collusion. By contrast, evidence points both to the corruption of Hillary Clinton with her email server and the Clinton Global Initiative as well as the Obama administrations abuse of power to spy on citizens working for the Trump campaign.

Continued here:
Anatomy of the collusion lie - Power Line (blog)

Promise of precision medicine depends on overcoming big obstacles – Healthcare IT News

Posted on by

Paul Cerrato says he first started researching precision medicine almost 30 years ago.

"Back then it wasn't called precision medicine, but when I was in graduate school I did my final master's thesis on 'biochemical individuality' that was the buzzword," said Cerrato, a healthcare journalist. "That was the beginnings of the thinking about personalizing care: trying to understand how each human body is different before they can figure out how to treat individuals."

Fast forward three decades and the excitement around precision medicine seems to finallybe at a tipping point thanks to maturing technology, more cost-effective gene sequencing and momentum-building federal projects such as the Precision Medicine Initiative and the Cancer Moonshot.

[Also:How Penn Medicine primed its IT infrastructure for precision medicine]

But the obstacles are also substantial from the high cost of drugs for precision oncology, lack of widespread interoperability, skepticism on the part of some clinicians and challenges related to patient engagement.

At the Healthcare IT News Precision Medicine Summit in Boston on June 12, Cerrato, along with Beth Israel Deaconess Medical Center CIO John Halamka, MD, will discuss the obstacles and opportunities facing personalized medicine.

Halamka knows well about the opportunities. And not just because he's a renowned expert on health information technology. His wife, Kathy, was successfully treated for breast cancer with help from some sophisticated precision medicine tools and techniques.

Cerrato and Halamka just finished a book together, Realizing the Promise of Precision Medicine, due to be published by Elsevier in October. In it, they offer some insights into Kathy's treatment, but focus more generally on the transformative potential of personalized care, exploring the role of electronic health records, patient-facing mobile apps, health information exchange and more.

They're hopeful about the future. But cognizant that some substantial hurdles will need to be overcome along the way.

"When we were researching the book there was a lot of positive data, but also quite a bit of skepticism, and criticism of the whole concept that precision medicine should have such an important role in patient care," said Cerrato.

One of the central goals of their book, and their talk in Boston this month, is to counter the misapprehension of many clinicians that precision medicine has limited applications in the real-world care settings.

For instance, he said, many physicians argue: "'Personalized medicine? We already do that. We don't need to spend another $200 or $300 million on a precision medicine initiative because we already provide personalized care on a daily basis.'

"Of course, the answer to that is, that's personalized care with a lower-case P," said Cerrato. "We're talking about something much more sophisticated and much more involved: genomics and microbiome and lots of other risk factors. The average doc might be personalizing medicine by switching from one antibiotic to another, or asking patients if they have liver disease before they decide to use a statin, or those kinds of things. That's personalization, but those are the baby steps."

Another objection has less to do with changing culture and mindset and more to do with financial realities, he said. And this one in the near term, at least has some merit.

"The second obstacle we're dealing with is the objection of some thought leaders in clinical medicine that precision medicine will simply cost too much," said Cerrato. "There's some substance to that objection. You look at the cost of precision medicine drugs that have been coming out the past couple years they're really astronomical. And the return on investment, very often, is limited, especially in cancer care," where hugely expensive drugs are sometimes only able to prolong life for a few months or a year.

"It's a work in progress," he said. "We don't have a simple answer to that. But we've got to put it out there. One of the reasons we want to give a presentation like this and write a book like this is we want to convince docs in the trenches, and thought leaders in clinical care, that precision medicine really is a model they should be following. In order to do that, we really should be up front about their criticisms. We have to address them directly."

Another common concern is that "physicians' workloads would be greatly increased if they had to start practicing precision medicine on a daily basis," said Cerrato. "You're talking about mountains and mountains of information. How do you translate that so a physician who only has 15 minutes with a patient can use that in daily care?"

Again, not an unreasonable point to make. Gene sequencing is still pretty expensive, too. But even if it cost a dollar, the average primary care physician does not know how to interpret genomic data."

Technology also poses big challenges, especially while interoperability remains elusive. "Without interoperability, precision medicine is really not going to get too far."

EHRs too are lagging badly in their ability to handle data-intensive genomics. "Right now we're not at the stage where a physician can just open up his electronic health record and say 'OK, what does this patient's gene sequencing look like?' We're not there yet."

But there are big reasons for optimism, too. As Halamka said, Kathy's treatment benefited greatly from technologies such as Clinical Query 2, software at Beth Israel Deaconess that allows physicians to see anonymized health records of cohorts of patients, tailored by different demographic and clinical parameters.

"It looks at all the patients who have had similar signs and symptoms and lab values and shows what were the treatment recommendations for those patients," said Cerrato. "It allowed the oncology team to individualize the care for Kathy so it would meet her needs, while eliminating the possibility of her getting treated with a protocol that would do more harm than good."

Most precision medicine and genomics work is still being done at advanced academic medical centers such as BIDMC, of course.

But on a smaller scale, there's still big promise for other types of personalized treatments.

"There are certain aspects of the field that are already happening right now. Especially in the field of diabetes, there's enough out there in terms of mobile apps and other digital tools, that is allowing physicians who are interested to practice precision medicine today," said Cerrato.

"Scripps has come out with an app for asthmatics, and it does a lot of the heavy lifting for clinicians by allowing patents to put in some basic parameters about their peak flow readings and their medication use and a few other things," he added. "When a doc uses that for the asthmatic patient, they don't have to do all the work. The technology of the app will do it for them. It has built-in decision trees to help them make better decisions on a personalized basis."

The bottom line, said Cerrato, is that there are some aspects of precision medicine that are working for some docs now and there are some aspects that remain in the future either because they're not educated enough to know how to do it, or the clinical data is not there yet."

How long it takes for genomics and personalized treatments to become commonplace still depends on the answers to a host of clinical, financial, technological and cultural questions, he said, but "I do think it will be the standard of care in the future."

Twitter:@MikeMiliardHITN Email the writer: mike.miliard@himssmedia.com

Like Healthcare IT News on Facebook and LinkedIn

Go here to see the original:
Promise of precision medicine depends on overcoming big obstacles - Healthcare IT News

Biotech: No Downside Risk Here – Barron’s

Posted on by

Barron's
Biotech: No Downside Risk Here
Barron's
Both the iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 1.5% and 2.4% respectively, so far on Thursday. Oppenheimer's Leah Rush Cann notes that biotech stocks are trading at a 30% premium to the market.
Compton Capital Management Inc. RI Boosts Position in iShares NASDAQ Biotechnology Index (IBB)The Cerbat Gem
Neville Rodie & Shaw Inc. Boosts Position in iShares NASDAQ Biotechnology Index (IBB)Sports Perspectives
Alethea Capital Management LLC Maintains Stake in iShares NASDAQ Biotechnology Index (IBB)Chaffey Breeze
BBNS
all 23 news articles »

Read more here:
Biotech: No Downside Risk Here - Barron's

Puma Biotechnology Inc (PBYI) Soars 6.73% on June 01 – Equities.com

Posted on by

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Thursday June 01 as shares jumped 6.73% to close at $81.65. About 2.99 million shares traded hands on 18,479 trades for the day, compared with an average daily volume of 1.39 million shares out of a total float of 36.97 million. After opening the trading day at $77.15, shares of Puma Biotechnology Inc stayed within a range of $84.10 to $76.90.

With today's gains, Puma Biotechnology Inc now has a market cap of $3.02 billion. Shares of Puma Biotechnology Inc have been trading within a range of $80.20 and $27.64 over the last year, and it had a 50-day SMA of $41.30 and a 200-day SMA of $43.66.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

See the article here:
Puma Biotechnology Inc (PBYI) Soars 6.73% on June 01 - Equities.com

Anatomy of a Goal: Ola’s Dagger – Massive Report

Posted on by

Welcome to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from the previous weeks Columbus Crew SC match.

For match 15 of the 2017 MLS Season, we take a look at Ola Kamaras 59th minute goal that put Columbus Crew SC up 3-0 as the final goal in a win over the Seattle Sounders on Wednesday.

Heres a look at the finish from the Crew SC striker.

Crew SC came out firing on all cylinders, scoring two first-half goals and putting Seattle on the defensive almost immediately. The Black & Gold defense held firm for much of the match, with Zack Steffen playing one of his best games to date. Seattle, without Chad Marshall, Clint Dempsey, Jordan Morris and most of their first choice backline, struggled to slow the Columbus attack.

I chose this goal instead of one of Columbus first two, because this third goal is the epitome of the Berhalter system working at its best. Specifically, this goal features a 10-pass sequence (with every pass on the ground), where nine different Crew SC players touched the ball, which traveled from the right side of the field to the left side, and ended with a goal right running right up the middle of the pitch.

This goal starts with a Jonathan Mensah header to fellow center-back Josh Williams off of a Seattle clearance.

Williams receives Jonathans header and takes the ball up the right side of the field, where he finds a wide open Hector Jimenez. A center back playing a ball out wide to a wingback, it doesnt get much more Behalter-system than that.

With the ball out wide, Crew SC center midfielder Artur checks to Jimenez who plays the simple pass to the Brazilian. Artur then turns to the middle of the field to survey his options.

Notice Federico Higuain, making a run on the left side of the image. The Black & Golds No. 10 also checked back to Jimenez and, after the ball was passed to Artur, he immediately made a run up the field, taking a defender along and opening up space for the Crew SC offense. So far, none of these passes have been pressured by Seattle.

Artur plays a simple square pass to his midfield compatriot, captain Wil Trapp, who, seeing that he has ample time and space, lets the ball run in front of him as he surveys his many options.

Immediately, Trapp has four options: a drop pass to Jonathan, a pass to left-back Jukka Raitala; carry the ball up the field himself or a difficult pass up the field to Justin Meram.

As pressure from Alvaro Fernandez arrives, Trapp opts for the safe option and slots a pass into the path of Raitala.

To this point, the ball has moved from the center backs, to the right back, to both central midfielders and now to the left back, all without much defensive pressure.

Seeing space ahead of him, Raitala carries the ball up the left side of the field, waiting for pressure from Seattle.

Ive highlighted this image to show this nifty move by Raitala. As Cristian Roldan begins to pressure him, Raitala does a quick cutback which leaves Roldan a few yards ahead of him and gives the Crew SC left back time and space to make a decision.

With about two yards of space, after making a clever move on Roldan, Raitala slots the ball to an unmarked Meram.

As Meram receives the ball, he is open and thus able to survey all of his options. The Crew SC winger could pass the ball back to his left back, dribble the ball up the field until he is defended, find Federico Higuain or pass a square ball to Artur.

Meram decides to dribble forward until he is engaged by Seattle right back Jordy Delem. As Delem begins to defend Meram, the Crew SC winger will initiate a brilliant series of one-touch-passes with Higuain, confusing Delem and setting up Merams eventual assist to Kamara.

Lets take a look at Meram and Higuains quick passing combo before we break it down.

After Merams first pass to Higuain, the Crew SC attacking midfielder makes a one-touch pass back to his winger. Delem, the only defender engaged with these Black & Gold attackers, switched pressure to Higuain after Merams initial pass and now is switching back to Meram after Higuains one-touch pass. A hallmark of possession-based systems like Columbus is putting offensive players into these two-on-one situations with the defending team.

As we saw in the build up to Ola Kamaras great goal in New England, Crew SC will use these rondo opportunities to confuse defensive players and open up an offensive players options to pass or dribble.

As Meram receives the pass from Higuain, and as Delem shifts back to Meram and prepares to shift back to Higuain, the Crew SC winger makes his run into open space. By making this run, Meram forces Delem to decide whether he will run with him or defend Higuain.

Merams run slows Delem just enough to give Higuain the opportunity to play another one-touch pass into the space ahead of his teammate, who has gotten around the delayed defender.

With Delem out of the picture, and with slight pressure from Oniel Fisher, Meram has two immediate options: continue dribbling forward toward the middle of the field or slot a pass into Kamara who is running the channel between Seattles center backs.

Meram, still not pressured, slots the ball between Fisher and Seattles right center back Gustav Svensson, as Kamara continues running that center channel.

Now, Kamara is in a footrace with Seattles defenders. If Kamara wins this race, he will have to immediately decide what to do with the ball, be it a shot with his left foot or a quick stab forward to create more space.

Kamara decides to fire a one-time shot with his left foot, looking to beat Stefan Frei on the back post just like Crew SCs previous two goals.

Kamara is able to hit an inch-perfect ball that bangs in off of Seattles back post and in.

Take a closer look at just how tough Olas shot was.

Findings:

Continued here:
Anatomy of a Goal: Ola's Dagger - Massive Report

Grey’s Anatomy: What will happen with Meredith and Nathan? – FanSided

Posted on by

GREY'S ANATOMY - "Ring of Fire" - The doctors' lives are at risk after a dangerous patient escapes the hospital room. Alex must make a hard choice in his relationship with Jo while Meredith has some big news for Nathan that brings things to a turning point, on the season finale of "Grey's Anatomy," THURSDAY, MAY 18 (8:00-9:01 p.m. EDT), on The ABC Television Network. (ABC/Richard Cartwright) ELLEN POMPEO

LeBron James responds to racist vandalism to his Los Angeles home by David Austin Bumpus

Roy Nelson says move to Bellator MMA gave him best quality of life by Kyle Symes

Greys Anatomyseason 13 ended with a bang, but perhaps the biggest revelation was that Owens sister Megan is still alive. Megan, who was previously engaged to Dr. Nathan Riggs, was found to be alive after missing for years and being presumed dead by everyone, including her brother and fiance. Now that Megan is alive, what will this mean for Merediths romance with Nathan?

According to TV Line, there are plenty of ways that this storyline could play out. At the end of the Greys Anatomyseason 13 finale, Meredith tells Nathan that Megan is alive and urges him to go to her, saying if Derek were still alive she would already be on her way to him. Its clear that Meredith understands the situation and wont want to stand in Nathans way of being happy with Megan. However, what about Merediths happiness?

Mere and Nathan were just getting started. They had jumped past all of their awkward relationship issues and went public with their romance. Meredith was even ready to introduce her new boyfriend to her three children. Now, everything has changed, and fans want to know how this situation will play out.

Perhaps Greys Anatomy will have Megan be so altered by her traumatic experience that she will want nothing to do with Nathan. This would free Nathan up to be with Meredith and feel less guilty about it. However, despite Megans mental and physical state, Nathan may realize that hes completely fallen for Meredith, and the two could spend season 14 being drawn to one another but trying to keep their distance for Megans sake.

Judging from a poll on the website, it looks like many viewers are hoping to see Meredith and Nathan together again during Greys Anatomyseason 14, most likely because Mere has already been through enough heartbreak in the past. It may be time for her to get a happy ending for once.

Here is the original post:
Grey's Anatomy: What will happen with Meredith and Nathan? - FanSided

IBM’s Watson – Best Doctor In The World? – Anti Aging News

Posted on by

The Watson supercomputer, created by technology company IBM, uses the power of artificial intelligence (AI) in ways that benefit mankind. In 2011, the world was introduced to the potential of AI when Watson won the title of world champion on the popular game show Jeopardy! In 2011.

Since then, Watsons developers have focused on customizing the AI for medical use. Programmers have integrated thousands of patient records, scores of medical texts, and all the content in the PubMed and Medline databases into Watsons working memory. In all, the AI has consumed 2 million pages of text that represent over 600,000 pieces of medical evidence, 25,000 training cases, and 14,700 hours of clinical training.

The Benefits of Using AI in Medical Diagnoses

AI programs, like Watson, are gaining importance in information-heavy fields, like medicine. The supercomputer is able to store more information than a human brain and can access the information more quickly. In addition, a computer-generated diagnosis is based on evidence and established fact, while human doctors may be swayed by cognitive biases or confidence issues.

The Watson AI uses an interface that allows users to speak to it in a natural way. The machine is able to gather and analyze information from patients and compare it to stored information. Based on this inquiry, the AI can then make an accurate diagnosis.

More than just comparing bits of information, the Watson supercomputer is able to form hypotheses independently. In a process that is similar to the way humans learn, the machine can then test and evaluate its own hypotheses, disregarding what doesnt work and adjusting for error.

In 2011, McAfee wrote about the advantages of using AI for medical purposes. AI diagnoses are based on the complete published body of medical knowledge, making it the most up-to-date medical resource. Diagnostic programs are also accurate, consistent, cost very little to operate, and can be used anywhere in the world.

AI: The Future in Medical Care

When using AI for diagnostics, a physician describes symptoms and other contributing factors to the program. The computer then mines patient history and its own databases, and along with test results and other pieces of medically relevant data, creates a hypothesis. The hypothesis is tested against its information on treatments, hospital records, and published studies and research. Once satisfied that the hypothesis is valid, Watson can then give a customized treatment plan for the patient.

While Watson has incredible capacity, only a few companies are taking advantage of it. MD Anderson Cancer Center uses AI to develop treatment plans for leukemia patients. The medical company WellPoint uses Watson-based software to allow patients to evaluate their doctors treatment plans.

Currently, the Watson AI is not able to fully use all of the information it has access to. Developers are working with the program to help it develop the mental agility and versatility of thought that makes human doctors so effective.

Read more here:
IBM's Watson - Best Doctor In The World? - Anti Aging News